The Pulse
Basecamp Research Raises $140M for AI-Designed Medicines
Basecamp Research has raised $140 million in an oversubscribed Series C led by S32 to advance its EDEN biological AI models and therapeutic pipeline. The London-based company plans to begin with in vivo cell therapy while expanding pharmace
AI.info Team ·
Basecamp Research has raised $140 million in an oversubscribed Series C financing to train new versions of its EDEN biological AI models and move a pipeline of AI-designed therapeutics toward clinical development. The round, announced September 23, 2026, is led by S32 and includes participation from NVIDIA, Anthropic’s Anthology Fund, the NATO Innovation Fund, The Rockefeller Foundation and True Ventures, among others.
The London- and Boston-based company says its first major therapeutic application will be in vivo cell therapy, an approach that reprograms a patient’s cells inside the body rather than removing and manufacturing them outside it. Basecamp says the financing will also support additional pharmaceutical partnerships and development work across several therapeutic areas.
Basecamp’s $140M Series C targets in vivo cell therapy
Basecamp combines biological AI models with technology designed to write long DNA sequences into cells. Its EDEN models are intended to design complex genetic payloads, while large serine recombinases can integrate those sequences into the genome at selected locations.
The company says that combination could support cell therapies that are more complex and easier to administer than current approaches. Existing cell therapies often depend on extracting a patient’s cells, modifying them in a manufacturing facility and returning them to the patient; Basecamp says those processes can cost hundreds of thousands of dollars per patient.
Basecamp has not announced a clinical candidate or a trial start date in the financing release. It describes the work as preclinical and says the pipeline is advancing toward clinical development.
EDEN is trained on Basecamp’s Trillion Gene Atlas
The company’s models are trained on the Trillion Gene Atlas, which Basecamp describes as the world’s largest proprietary biological AI training dataset. The Atlas draws on data collected through access-and-benefit-sharing partnerships in more than 30 countries across all seven continents, with sequencing and infrastructure support from partners including NVIDIA, Anthropic, PacBio and Ultima Genomics.
Basecamp says EDEN is designed to identify patterns across previously unseen biology rather than focus on one scientific task. Its stated applications include cell and gene therapies, enzymes and peptides. The company has also made two EDEN capabilities—antibiotic design and antigen immunogenicity prediction—available through Anthropic’s Claude Science platform, according to its company website.
Glen Gowers says the company wants to reprogram the body
“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” said Glen Gowers, co-founder and CEO of Basecamp Research, in the company’s financing announcement. “AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.”
André Hoffmann, vice-chairman of Roche, is among the additional investors in the round. He said Basecamp had built a platform spanning biological data, trained models and designed therapies, and described personalised, AI-designed therapeutics as a new stage in medicine’s development.
Andy Conrad, general partner at S32 and former CEO of Google’s Verily, will join Basecamp’s board. He said the combination of AI, biological data and scientific insight could affect disease research and medicine development, but the company’s financing announcement does not provide clinical efficacy data or a timetable for human studies.
Richard Pearce joins as Basecamp expands pharma ties
Basecamp has appointed Richard Pearce as chief business officer to expand its pharmaceutical partnerships. The release identifies Pearce as formerly of Biogen and says he will work on business development, though it does not name specific new commercial agreements tied to the financing.
The company’s immediate program is therefore defined more by platform and preclinical work than by a named drug. Basecamp is starting with in vivo cell therapy, backed by EDEN’s DNA-design capabilities and the company’s recombinase technology; the announcement gives no candidate name or clinical-trial timetable.